| HOME >> BIOLOGY >> TECHNOLOGY |
Net income (loss) per
common share -
basic and diluted $(0.21) $ (0.16) $(0.65) $(0.50)
Weighted average shares
outstanding -
Basic and diluted 10,927 10,884 10,912 10,843
Reconciliation of Non-GAAP
Financial Measures:
Net income (loss) $(2,249) $(1,764) $(7,092) $(5,451)
Less: DelSite grant income 776 811 1,399 1,506
Plus: DelSite expenses 1,300 1,503 3,575 3,985
Pro forma profit (loss)
before DelSite $(1,725) $(1,072) $(4,916) $(2,972)
CARRINGTON LABORATORIES, INC
Condensed Consolidated Balance Sheets
(in thousands)
September 30, December 31,
2007 2006
(unaudited) (audited)
ASSETS:
Current Assets:
Cash and cash equivalents $3,253 $878
Cash, restricted 489 -
Accounts receivable, net 2,337 2,659
Inventories, net 3,786 3,405
Prepaid expenses 427 155
Total current assets 10,292 7,097
Property, plant and equipment, net 5,460 6,093
Customer relationships, net 55 199
Other assets, net 1,547 609
Total assets $17,354 $13,998
LIABILITIES AND SHAREHOLDERS' EQUITY:
Current Liabilities:
Line of credit $2,000
'/>"/>
| SOURCE Carrington Laboratories, Inc. Copyright©2007 PR Newswire. All rights reserved |